Trimethadione

This article is about the drug Tridione. For the content management software Tridion, see SDL plc.

Trimethadione

Systematic (IUPAC) name
3,5,5-trimethyl-1,3-oxazolidine-2,4-dione
Clinical data
Trade names	Tridione
AHFS/Drugs.com	Micromedex Detailed Consumer Information
Pregnancy category	X
Legal status	℞ (Prescription only)
Routes of administration	Oral
Pharmacokinetic data
Bioavailability	High
Metabolism	Demethylated to dimethadione
Biological half-life	12–24 hours (trimethadione) 6–13 days (dimethadione)
Excretion	Renal
Identifiers
CAS Number	127-48-0 Y
ATC code	N03AC02 (WHO)
PubChem	CID: 5576
IUPHAR/BPS	7316
DrugBank	DB00347 Y
ChemSpider	5374 Y
UNII	R7GV3H6FQ4 Y
KEGG	D00392 Y
ChEMBL	CHEMBL695 Y
Chemical data
Formula	C6H9NO3
Molecular mass	143.141 g/mol
SMILES O=C1N(C(=O)OC1(C)C)C
InChI InChI=1S/C6H9NO3/c1-6(2)4(8)7(3)5(9)10-6/h1-3H3 Y Key:IRYJRGCIQBGHIV-UHFFFAOYSA-N Y
(verify)

Trimethadione is an oxazolidinedione anticonvulsant. It is most commonly used to treat epileptic conditions that are resistant to other treatments.

Fetal trimethadione syndrome

If administered during pregnancy, fetal trimethadione syndrome may result causing facial dysmorphism (short upturned nose, slanted eyebrows), cardiac defects, intrauterine growth restriction (IUGR), and mental retardation. The fetal loss rate while using trimethadione has been reported to be as high as 87%.

External links

• MedlinePlus DrugInfo medmaster-a601127
• DDB 30479